Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Alora
Overview
What is Alora?
Alora
Alora
in vivo
Alora
Alora
Product meets USP
What does Alora look like?
What are the available doses of Alora?
Sorry No records found.
What should I talk to my health care provider before I take Alora?
Sorry No records found
How should I use Alora?
Alora
Alora
Alora
Alora
should not be applied to the breasts.
In the event that a system should fall off, the same system may be reapplied. If necessary, a new system may be applied to another site. The original treatment schedule should be maintained.
What interacts with Alora?
Sorry No Records found
What are the warnings of Alora?
Sorry No Records found
What are the precautions of Alora?
Sorry No Records found
What are the side effects of Alora?
Sorry No records found
What should I look out for while using Alora?
Alora
See
The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer.
What might happen if I take too much Alora?
Serious ill effects have not been reported following acute ingestion of large doses of estrogen containing drug products by young children. Overdosage of estrogen may cause nausea and vomiting, and withdrawal bleeding may occur in females.
How should I store and handle Alora?
Store at 20ºC to 25°C (68ºF to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) . Protect 3 mg and 4.5 mg capsules from light to prevent potential color fading.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.AloraNDC 0023-5885-12AloraNDC 0023-5886-15AloraNDC 0023-5887-17AloraNDC 0023-5888-11Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Do not store unpouched. Apply immediately upon removal from the protective pouch.Discard used in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.Keep out of reach of children.For all medical inquiries contact:AllerganMedical Communications 1-800-678-1605Distributed by: Allergan USA, Inc.Irvine, CA 92612Rev. 02/2018© 2018 Allergan. All rights reserved.ALORA® is a registered trademark of Allergan Sales, LLC.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.
Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.
Non-Clinical Toxicology
AloraSee
The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer.
Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem hydrochloride concomitantly with any agents known to affect cardiac contractility and/or conduction (see ). Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem hydrochloride (see ).
As with all drugs, care should be exercised when treating patients with multiple medications. Diltiazem is both a substrate and an inhibitor of the cytochrome P450 3A4 enzyme system. Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.
1.
Addition of a progestin when a woman has not had a hysterectomy
.
Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.
There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include:
2.
Elevated blood pressure
.
In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen. Blood pressure should be monitored at regular intervals with estrogen use.
3.
Hypertriglyceridemia
.
In patients with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis and other complications.
4.
Impaired liver function and past history of cholestatic jaundice
.
Estrogens may be poorly metabolized in patients with impaired liver function. For patients with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued.
5.
Hypothyroidism
.
Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Patients with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T and T serum concentrations in the normal range. Patients dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These patients should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.
6.
Fluid retention
.
Because estrogens may cause some degree of fluid retention, conditions which might be influenced by this factor, such as patients with asthma, epilepsy, migraine, and cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.
7.
Ovarian cancer
.
The CE/MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE/MPA vs. placebo was 1.58 (95% confidence interval 0.77-3.24) but was not statistically significant. The absolute risk for CE/MPA vs. placebo was 4.2 vs. 2.7 cases per 10,000 women-years.
A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48) and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
8.
Exacerbation of endometriosis
.
Endometriosis may be exacerbated with administration of estrogens. A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen alone therapy. For patients known to have residual endometriosis post-hysterectomy, the addition of progestin should be considered.
9.
Hypocalcemia
.
Estrogens should be used with caution in individuals with severe hypocalcemia.
10.
Exacerbation of other conditions
.
Estrogens may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.
See
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
Incidence of adverse events > 2% of each treatment group is given in Table 5.
The following additional adverse reactions have been reported with estrogens and/or progestin therapy:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).